Aeglea BioTherapeutics Shares Plummet Following Refusal To File Letter From FDA

Aeglea BioTherapeutics, Inc. AGLE announced the U.S. Food and Drug Administration (FDA) has refused to accept the company’s Biologics License Application (BLA) with a Refusal to File (RTF) letter.

The company filed the BLA in April for its lead drug candidate pegzilarginase for the treatment of Arginase 1 Deficiency (ARG1-D), based on positive results from PEACE Phase 3 study as well as a Phase 1/2 clinical trial and its open-label extension study.

Arginase 1 Deficiency is a rare, progressive and debilitating disease characterized by high levels of arginine.

The FDA communicated in the RTF letter, requesting additional data to support effectiveness, such as evidence showing that plasma arginine and metabolite reduction predicts clinical benefit in patients with ARG1-D.

Anthony Quinn, president and chief executive officer, commented : “While we are disappointed in the outcome of the FDA's initial review of our BLA, we continue to believe in the potential of pegzilarginase and thank the FDA for their constructive comments and ongoing collaboration.”

Shares of Aeglea BioTherapeutics are trading down 33% at $1.01 in the regular market session.

Posted In: FDA warningBiotechNewsPenny StocksHealth CareFDAMoversTrading IdeasGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.